# Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer

> **NCT01142388** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 94 (actual)

## Conditions studied

- Metastatic Esophageal Adenocarcinoma
- Metastatic Esophageal Squamous Cell Carcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Recurrent Esophageal Adenocarcinoma
- Recurrent Esophageal Carcinoma
- Recurrent Esophageal Squamous Cell Carcinoma
- Recurrent Gastroesophageal Junction Adenocarcinoma
- Stage IV Esophageal Cancer AJCC v7

## Interventions

- **BIOLOGICAL:** Cixutumumab
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Paclitaxel
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01142388
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2010-09-21
- **Primary completion:** 2014-07-15
- **Final completion:** 2027-03-31
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01142388

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01142388, "Paclitaxel With or Without Cixutumumab as Second-Line Therapy in Treating Patients With Metastatic Esophageal Cancer or Gastroesophageal Junction Cancer". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT01142388. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*